Objective To investigate the relationship of Vaneomycin serum concentration and drug adverse reactions (ADRs) in neonates.Methods Two hundred and thirteen neonates who were treated by Vancomycin and had their serum concentration monitored were recruited.The number of cases which had liver,kidney and hearing damage after treatment was calculated.The correlation between 3 different serum concentrations (＜5 mg/L,5-10 mg/L,＞ 10 mg/L) and ADRs were analyzed.Results The mean level of Vancomycin in serum was (4.36 ± 4.99) mg/L The total incidence of ADRs was 17.8％ (38/213 cases).The main ADRs were liver damage and hearing impairment,whose incidences were 9.9％ (21/213 cases) and 7.5％ (16/213 cases),respectively,and they were were significantly higher than kidney danage (0.5％,1/213 cases) (x2 =19.172,P =0.000;x2 =13.785,P =0.000).There was no significant difference be-tween the inidence ratio of liver damage and that of the hearing impairment (x2 =0.330,P =0.566).The ADRs ratio among 3 different serum concentrations was 17.0％ (24/141 cases),17.6％ (9/51 cases) and 23.8％ (5/21 cases).There was no significant difference between the ADRs ratios and distribution of different serum concentrations (x2 =0.576,P =0.750).Moreover,the ADRs rates didn't increase along with the serum concentrations (Z =0.648,P =0.517).Except for aspartate transaminase,the indicators of liver and kidney function varied significantly after vancomycin treatment (P ＜0.05).But there was no clinical significance because the mean value was in normal range.By Bivariate Correlation analysis,Vancomyein serum concentration had no significant influence on liver and kidney function (P ＞ 0.05).Conclusions Neonates treated by Vancomycin had reatively high ratio of the liver damage and the hearing impairment.There is no significant correlation between Vancomyein serum concentration and ADRs in neonates.

In recent years， countries around the world have invested a lot of resources in neuroimaging research on brain function and diseases. The abundant and more easily accessible neuroimaging data will have a profound impact on the research of cognitive neuroscience and psychiatry， thereby assisting the development of the diagnosis and treatment of brain diseases. At present， neuroimaging data sharing is gradually becoming a trend， but it is also worth considering of some unique ethical issues that come with it. Therefore， from the four shared entities of the public， researchers， users， and data centers， this paper sorted out the ethical issues in neuroimaging data sharing， and deeply analyzed the reasons for these issues. Based on the responsibility ethics and combined with the guidance of the Belmont principles， governance responses were proposed， including strengthening the construction of neuroethics committees， improving informed consent models， building data sharing infrastructure， establishing data privacy protection mechanisms， and introducing regulatory protections， to provide a certain reference for promoting the neuroimaging data sharing and maximizing the contribution of participants.